We are impatient for the patients we serve.
We are driven to deliver safe and effective therapies to patients as quickly as possible. To do this, we are advancing a pipeline of potential first-in-class medicines targeting rare diseases with significant unmet needs and oftentimes no approved treatment options.
Our efforts are led by late-stage development programs of sparsentan, which is a novel product candidate targeting rare kidney diseases – focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN).
We are also partnering with leaders in patient advocacy and the National Institutes of Health (NIH) on earlier-stage development work in rare liver diseases. In addition, pegtibatinase (TVT-058), the first potential disease-modifying therapy for the treatment of classical homocystinuria (HCU), is in Phase 1/2 development.
Today we aim to help patients with our four approved commercial therapies, Chenodal® (chenodiol), Cholbam® (cholic acid), Thiola® (tiopronin), and Thiola EC® (tiopronin) delayed-release tablets. We are committed to broad access for our FDA-approved therapies, and we provide personalized clinical support services through the Total Care Hub. We also sponsor diagnostic testing at no cost to qualified patients to help accurately diagnose a variety of disorders.
Laura Clague and Eric Dube Named to San Diego Business Journal SD 500 Most Influential People in San Diego
NewsNovember 29, 2021
Today, the San Diego Business Journal named our president and CEO Eric Dube, Ph.D., and our CFO Laura Clague in the top 500 executives in San Diego for 2021. With Eric’s commitment to inclusion and belonging, this native San Diegan leads by example at Travere — and in our industry. Laura is a recognized advocate for women in the workplace and serves as an active mentor for women in STEM careers in the San Diego community.